Pasithea Therapeutics (KTTA) said Tuesday it priced a $5 million public offering consisting of nearly 3.6 million common shares, or pre-funded warrants, at $1.40 per share.
The offering includes series C warrants, which expire in five years, and series D warrants, which expire in 18 months, both exercisable at $1.40 per share.
The offering is expected to close around Wednesday, pending the fulfillment of customary closing conditions.
The company plans to use the proceeds for general corporate purposes such as research, clinical trials, technology development, potential acquisitions, and working capital, the company said.
Shares of the biotechnology company rose more than 35% in recent Tuesday trading.
Price: 1.92, Change: +0.50, Percent Change: +35.21
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。